Special Issue "Advances and Perspectives in Radiotherapy Treatments"
A special issue of Medicines (ISSN 2305-6320).
Deadline for manuscript submissions: closed (30 November 2018).
Assoc. Prof. Dr. Spyros Manolopoulos
1. School of Physics, University of Warwick, Coventry, CV4 7AL, UK
2. University Hospitals Coventry and Warwickshire, Arden Cancer Centre, Clifford Bridge Road, Coventry CV2 2DX, UK
† Now at GenesisCare, 69 Alma Road, Windsor SL4 3ES, UK
Website | E-Mail
Phone: +44 2476 967258
Interests: radiotherapy; treatment planning; clinical radiotherapy trials; IMRT; IGRT; VMAT; SBRT; SRT; protontherapy; particle therapy; proton CT; theragnostics; dose escalation
Radiotherapy (RT) is an effective and efficient cancer treatment, with around 4 in 10 patients whose cancer is cured having received radiotherapy as part of their treatment (“Achieving world-class cancer outcomes; a strategy for England 2015-2020, CRUK, 2015). It is suggested that RT should be offered to ca. 50% of cancer patients (“The role of radiotherapy in cancer treatment”, Delaney et al., Cancer, 104 (2005) pp. 1129-1137). RT is a highly-technical treatment modality, in which effectiveness relies greatly on technological advances. This has manifested itself in recent years, with cutting-edge imaging that allows for more accurate treatments, computing technology that sped up and increased the accuracy of treatment planning and dose calculation, and radiation beam delivery techniques that have helped to target the dose more optimally. As a result, there is well founded optimism that the outcome of radiotherapy treatments will continue to improve, both in disease control and quality of life for patients.
This prompted national governments to invest in radiotherapy and for example in the UK NHS England is implementing the largest radiotherapy upgrade programme in 15 years, aiming for all patients to have access to high-quality, modern radiotherapy treatments. As a result, over 50 radiotherapy treatment machines (linacs) in at least 34 hospitals nationwide are being replaced or upgraded, with a final aim to replace all linacs that are more than 10 years old, with modern ones that offer real time IG-VMAT as minimum specification (“Next steps on the NHS five year forward view”, NHS England, 2017).
Research should also be an integral part of the radiotherapy service, as it helps developing new treatment techniques to improve outcomes. Clinical trials are the best way to evaluate new ideas and implement them safely in the clinic. For clinical research to be conducted effectively it is imperative that further steps are taken apart from modernising the treatment machines, such as earlier diagnosis, new treatment strategies aiming for personalised radiotherapy and robust and comprehensive collection of treatment outcome data (“Principles for supporting radiotherapy clinical research in England”, CRUK, 2016).
The purpose of this Special Issue is to publish or review research related to contemporary radiotherapy and future advances.
Assoc. Prof. Dr. Spyros Manolopoulos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- treatment planning
- radiotherapy treatment techniques
- proton therapy
- particle therapy
- targeted therapy